Ontology highlight
ABSTRACT:
SUBMITTER: Patzke CL
PROVIDER: S-EPMC7074083 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Patzke Ciera L CL Duffy Alison P AP Duong Vu H VH El Chaer Firas F Trovato James A JA Baer Maria R MR Bentzen Søren M SM Emadi Ashkan A
Journal of clinical medicine 20200216 2
Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (<i>p</i> = 0.027 ...[more]